🔎 Trials Near Me

Gara Jalqabaatti › Burkitt Lymphoma › Idaho

Qorannoo klinikaalii Burkitt Lymphoma Idaho keessatti

Qorannoo 6 Burkitt Lymphoma f Idaho keessatti hirmaatuu jiru.

Magaalota Idaho keessatti

Takkalaa qorannoo (Ingiliffa)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
Namoota walitti qabaa jiraSadarkaa 2
366 Days – 46 Years · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Boise, Boise
  • Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
  • Kootenai Health - Coeur d'Alene, Coeur d'Alene
  • fi 3 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 39 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Nampa, Nampa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Saint Luke's Cancer Institute - Boise, Boise
Namoota walitti qabaa jiraSadarkaa 2
365 Days · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 1 hanga 30 · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Saint Luke's Cancer Institute - Boise, Boise
Namoota walitti qabaa jiraSadarkaa 3
365 Days – 25 Years · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT03959085

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.